Patel C K, Bui T A, Gregariou G, Pereira S, Chopdar A, McLeod B K
Clinical Cataract Research Unit, Oxford Eye Hospital, Radcliffe Infirmary, UK.
Eye (Lond). 1995;9 ( Pt 3):337-40. doi: 10.1038/eye.1995.65.
Tropicamide Novel Ophthalmic Delivery System (NODS) and guttae (g.) phenylephrine 10% was applied once, 2 hours before cataract surgery, as an alternative to our standard pre-operative regime of g. cyclopentolate 1% and g. phenylephrine 10% used four times before surgery. The two treatment groups were compared using a randomised, prospective, observer-masked study design. The horizontal pupil diameter was significantly smaller using the new regime but the per-operative decrease in diameter was not significantly different, suggesting that surgical miosis was not influenced by reducing the number of mydriatic applications. There was no difference in the subjective grading of the pupil, suggesting that adequate mydriasis suitable for cataract surgery was obtained using the alternative regime. No major complications were documented in relation to the use of NODS. We discuss why less intensive mydriasis is likely to be as efficacious and describe its potential advantages.
托吡卡胺新型眼用给药系统（NODS）和10%苯肾上腺素滴眼液在白内障手术前2小时使用一次，作为我们标准术前用药方案（术前使用4次1%环喷托酯滴眼液和10%苯肾上腺素滴眼液）的替代方案。采用随机、前瞻性、观察者盲法研究设计对两个治疗组进行比较。使用新方案时水平瞳孔直径明显较小，但术中直径减小无显著差异，这表明手术性瞳孔缩小不受减少散瞳用药次数的影响。瞳孔主观分级无差异，这表明使用替代方案可获得适合白内障手术的充分散瞳效果。未记录到与使用NODS相关的重大并发症。我们讨论了为什么较少强度的散瞳可能同样有效，并描述了其潜在优势。
